NCT03348670 2025-08-17Drugs-SNPsMedicine Invention Design, IncPhase 2/3 Active not recruiting600 enrolled
NCT04887506 2024-01-16TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate CancerTavanta TherapeuticsPhase 3 Completed107 enrolled 20 charts
NCT00089609 2018-04-20Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate CancerNational Institutes of Health Clinical Center (CC)Phase 2 Completed73 enrolled 16 charts
NCT00514267 2015-08-13An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid TumorsAstellas Pharma IncPhase 1/2 Completed32 enrolled
NCT00385827 2014-08-20A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)Centocor, Inc.Phase 2 Terminated106 enrolled 13 charts
NCT00357084 2010-09-14Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell TransplantFred Hutchinson Cancer CenterPhase 2 Completed53 enrolled
NCT00089856 2008-11-05GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate CancerCell GenesysPhase 3 Terminated626 enrolled
NCT00133224 2008-09-23Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer PatientsCell GenesysPhase 3 Terminated408 enrolled